Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Brunet

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Psycho-Oncology|March 3, 2018
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across SpainI Esteban, M Vilaró, E Adrover, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
Oncogene|December 20, 2016
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibitionF Mateo, E J Arenas, H Aguilar, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Psycho-Oncology|March 3, 2018
Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across SpainI Esteban, M Vilaró, E Adrover, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
Oncogene|December 20, 2016
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibitionF Mateo, E J Arenas, H Aguilar, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 13